Showing results (1341-1350 of 1,379) with videos related to

Sort By:
Pageof 138
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2020
Household Transmission of Carbapenemase-producing Enterobacterales in Ontario, CanadaAlainna J Jamal, Amna Faheem, Lubna Farooqi, et al.
Human Molecular Genetics|March 2, 2011
Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumptionPatrick Sulem, Daniel F Gudbjartsson, Frank Geller, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
A new class of penicillin-binding protein inhibitors to address drug-resistant <i>Neisseria gonorrhoeae</i>Tsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase ActivatorsXiaohui Du, Ronald J Hinklin, Yumei Xiong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
Journal of Dental Research|September 24, 2011
Genome-wide association scan for childhood caries implicates novel genesJ R Shaffer, X Wang, E Feingold, et al.
Cancer Research|July 12, 2020
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP Jake Slavish, Liying Chi, Mi-Kyung Yun, et al.
Nature Microbiology|April 8, 2026
A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeaeTsuyoshi Uehara, Allison L Zulli, Brittany Miller, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Pageof 138